Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,209
Total Claims
$1.7M
Drug Cost
825
Beneficiaries
$2,022
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-97%
Opioid rate vs peers
0.1% vs 2.6% avg
+89%
Cost per patient vs peers
$2,022 vs $1,068 avg
+67%
Brand preference vs peers
15.0% vs 9.0% avg
Opioid Prescribing
0.1%
Opioid Rate
16
Opioid Claims
$50
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,721 claims · $1.3M
Generic: 15,421 claims · $411K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Alpha-1-Proteinase Inhibitor | 13 | $245K |
| Sitagliptin Phosphate | 237 | $172K |
| Mirabegron | 101 | $59K |
| Apixaban | 87 | $58K |
| Levothyroxine Sodium | 722 | $54K |
| Semaglutide | 51 | $54K |
| Semaglutide | 45 | $51K |
| Dulaglutide | 39 | $38K |
| Fluticasone/Umeclidin/Vilanter | 32 | $31K |
| Rivaroxaban | 42 | $28K |
| Sitagliptin Phos/Metformin Hcl | 39 | $28K |
| Tiotropium Bromide | 32 | $28K |
| Empagliflozin | 28 | $25K |
| Tirzepatide | 23 | $25K |
| Fluticasone/Vilanterol | 43 | $25K |
Prescribing Profile
Patient Profile
73
Avg Age
73%
Female
0.98
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data